Previous 10 | Next 10 |
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.79% on the day to $107.67. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery an...
2024-01-09 10:45:10 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call P...
2024-01-09 08:35:20 ET BT Brands ( BTBD ) +135% . Sentage Holdings ( SNTG ) +95% . Juniper Networks ( JNPR ) +23% jumps 25% on report HPE is nearing buyout deal. Syra Health ( SYRA ) +17% . Elicio Therapeutics ( ELT...
2024-01-09 07:15:00 ET Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta Therapeutics (NASDAQ: SRPT) and DexCom (NASDAQ: DXCM) . These ...
2024-01-08 13:15:23 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics Q3 2023 Earnings Call Transcript Sarepta Therapeutics 2023 Q3 - Results - Earnings Call Presentation ...
– Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023 – Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for full-year 2023, significantly exceeding consensus ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-04 07:30:00 ET Summary Dyne Therapeutics' early trial results for DM1 and DMD treatments show dose-dependent improvements, but data is preliminary. Despite promising DYNE-101 and DYNE-251 outcomes, limited participant numbers and short trial durations constrain robust asse...
2024-01-03 07:15:08 ET More on Dyne Therapeutics Seeking Alpha’s Quant Rating on Dyne Therapeutics Historical earnings data for Dyne Therapeutics Financial information for Dyne Therapeutics For further details see: Dyne surges on positive Phase 1/2...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...